Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Major Depressive Disorder Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The global market for major depressive disorder treatments has experienced consistent expansion recently. Projections indicate a rise from $6.26 billion in 2025 to $6.44 billion by 2026, reflecting a compound annual growth rate of 2.9%. This upward trajectory during the past period is largely due to a rise in diagnosed depressive disorders, heightened public consciousness surrounding mental well-being, a greater accessibility of antidepressant pharmaceuticals, the broadening of mental health service provisions, and enhanced diagnostic criteria for mood-related conditions.

The market for major depressive disorder is poised for consistent expansion within the upcoming years, projected to reach $7.49 billion by 2030 with a CAGR of 3.9%. This anticipated growth trajectory is underpinned by several key factors, including the escalating mental health challenges stemming from lifestyle-related stress, the increasing integration of digital mental health solutions, a burgeoning need for tailored depression therapies, broader insurance accessibility for mental health services, and ongoing advancements in neuromodulation treatments. Furthermore, significant market trends to observe during this period encompass a greater embrace of combined therapeutic strategies, a heightened interest in non-invasive brain stimulation techniques, improved recognition and diagnosis rates for depression, the wider availability of telepsychiatry and remote mental healthcare, and a growing acceptance of innovative and swift-acting antidepressant medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Major Depressive Disorder Market Growth Momentum: Which Factors Are Influencing Demand?

Increased instances of addiction to drugs and alcohol are anticipated to be a primary catalyst for the expansion of the major depressive disorder market. Patterns of substance and alcohol consumption that are both excessive and detrimental, resulting in adverse effects on physical, psychological, and social well-being, are encompassed by the terms “substance abuse” and “alcohol abuse.” Major depressive disorder frequently coexists with these issues, creating a cycle where each condition exacerbates the other, thereby substantially elevating the potential for physical and mental health deterioration. Illustrating this point, data released in July 2024 by the Substance Abuse and Mental Health Services Administration, a U.S. governmental body focused on health and human services, revealed that 3.1 percent of individuals, amounting to 8.9 million people, engaged in opioid misuse during 2023, and a notable 21.8 percent of the population aged 12 and above consumed marijuana, establishing it as the most prevalent illicit substance. Furthermore, nicotine vaping among individuals aged 12 and over in the preceding month was reported by 9.4 percent, indicating a rise from the 8.3 percent recorded in 2022. Consequently, the increasing prevalence of substance and alcohol abuse is a significant factor contributing to the growth trajectory of the major depressive disorder market.

Major Depressive Disorder Market Segment Breakdown: Which Categories Generate The Most Revenue?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Major Depressive Disorder Market Trends Reshaping Industry Growth

Leading pharmaceutical entities participating in the major depressive disorder (MDD) space are prioritizing the creation of novel approaches, including prescription digital therapeutics (PDTs), to address the growing need for accessible, evidence-based psychotherapy, supplementary treatments for individuals with residual symptoms, and care models that leverage remote monitoring and data. PDTs represent software-based medical interventions that, once prescribed, deliver therapeutically validated content alongside tools for remote patient engagement, adherence tracking, and data collection for healthcare providers, offering a standardized, repeatable, and remotely supervised alternative to traditional medications or in-person therapy, particularly beneficial where access to specialized care is restricted. As an illustration, Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, introduced Rejoyn (initially designated CT-152) in April 2024, a PDT endorsed by the U.S. FDA as a complementary therapy for adults diagnosed with MDD currently undergoing pharmacotherapy, which involves a six-week, mobile-based regimen incorporating scientifically validated cognitive-emotional exercises (the Emotional Faces Memory Task/EFMT) and concise educational modules aimed at improving emotional regulation. This application operates through a prescribed channel where patients install and engage with scheduled sessions on their mobile devices, while clinicians oversee prescription and track patient progress, demonstrating efficacy in symptom reduction compared to a control group in the MIRAI randomized trial, distinguishing itself with a neuromodulatory framework targeting emotion-related neural circuits, personalized remote adherence prompts, and its classification as a regulated medical device.

Major Depressive Disorder Market Key Players And Strategic Industry Positioning

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Major Depressive Disorder Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model